-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic pancreatitis (CP) can cause the loss of pancreatic endocrine and exocrine functions, and cause serious sequelae, and cause irreversible damage to the pancreas
Chronic pancreatitis (CP) can cause the loss of pancreatic endocrine and exocrine functions, and cause serious sequelae, and cause irreversible damage to the pancreas
diabetes
To this end, the researchers used dual-energy X-ray absorptiometry (DXA, n=78, before TPIAT, n=65, paired 12 months before and after TPIAT) to measure the BMD of the whole body, lumbar spine, and left and right hip joints of 78 patients , BMD Z-score and bone mineral content (BMC), and use paired and two-sample t-test, linear regression and Fisher's exact test to test the relationship with the clinical history including age, smoking status, and drugs
The results of the study showed that among the patients tested by DXA before TPIAT treatment, 12% had low BMD (Z-core≤-2)
The author said at the end of the study: CP patients treated with TPIAT will have a decline in body, waist, and hip BMD in the first year after TPIAT, but these conditions gradually stabilized and no longer changed within 12 to 18 months after TPIAT
The author said at the end of the study: CP patients treated with TPIAT will have a decline in body, waist, and hip BMD in the first year after TPIAT, but these conditions gradually stabilized and no longer changed within 12 to 18 months after TPIAT
Jillian K.
Reduced bone mineral density in the first year after total pancreatectomy with islet autotransplantation (TPIAT).
Leave a message here